Literature DB >> 16044444

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Morie A Gertz1, Ray Comenzo, Rodney H Falk, Jean Paul Fermand, Bouke P Hazenberg, Philip N Hawkins, Giampaolo Merlini, Philippe Moreau, Pierre Ronco, Vaishali Sanchorawala, Orhan Sezer, Alan Solomon, Giles Grateau.   

Abstract

We undertook this study to develop uniformly accepted criteria for the definition of organ involvement and response for patients on treatment protocols for immunoglobulin light-chain amyloidosis (AL). A consensus panel was convened comprising 13 specialists actively involved in the treatment of patients with amyloidosis. Institutional criteria were submitted from each, and a consensus was developed defining each organ involved and the criteria for response. Specific criteria have been developed with agreed on definitions of organ and hematologic response as a result of discussions at the 10th International Symposium on Amyloid and Amyloidosis held in Tours, France, April 2004. These criteria now form the working definition of involvement and response for the purposes of future data collection and reporting. We report criteria that centers can now use to define organ involvement and uniform response criteria for reporting outcomes in patients with light-chain AL. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044444     DOI: 10.1002/ajh.20381

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  306 in total

1.  High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.

Authors:  Sumit Madan; Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; David Dingli; S Vincent Rajkumar; William J Hogan; Nelson Leung; Martha Grogan; Morie A Gertz
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

2.  [Systemic amyloidoses].

Authors:  S Schönland; N Blank; A V Kristen; J Beimler; T Ganten; U Hegenbart
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

3.  Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.

Authors:  Vaishali Sanchorawala
Journal:  Am J Blood Res       Date:  2012-01-01

4.  Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.

Authors:  Shaji Kumar; Angela Dispenzieri; Jerry A Katzmann; Dirk R Larson; Colin L Colby; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Nelson Leung; Steve R Zeldenrust; Marina Ramirez-Alvarado; Raynell J Clark; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  Blood       Date:  2010-08-26       Impact factor: 22.113

5.  Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement.

Authors:  A M Cornelison; R M Saliba; A Afrough; Y Dinh; Y Nieto; Q Bashir; N Shah; S Parmar; C Hosing; U Popat; E Shpall; R Champlin; M H Qazilbash
Journal:  Bone Marrow Transplant       Date:  2015-10-19       Impact factor: 5.483

6.  Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy.

Authors:  S Hong; J Valent; L Rybicki; D Abounader; B Bolwell; R Dean; A T Gerds; D Jagadeesh; B K Hamilton; B Hill; M E Kalaycio; B Pohlman; F Reu; C Samaras; R Sobecks; N S Majhail; H D Liu
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

7.  Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation.

Authors:  Ashutosh D Wechalekar; Mark Offer; Julian D Gillmore; Philip N Hawkins; Helen J Lachmann
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-17

8.  Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.

Authors:  Abdullah S Al Saleh; M Hasib Sidiqi; Eli Muchtar; Angela Dispenzieri; Francis K Buadi; David Dingli; Martha Q Lacy; Rahma M Warsame; Wilson I Gonsalves; Taxiarchis V Kourelis; William J Hogan; Suzanne R Hayman; Prashant Kapoor; Shaji K Kumar; Morie A Gertz
Journal:  Biol Blood Marrow Transplant       Date:  2019-05-02       Impact factor: 5.742

9.  Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.

Authors:  Ping Zhou; Julie Teruya-Feldstein; Ping Lu; Martin Fleisher; Adam Olshen; Raymond L Comenzo
Journal:  Blood       Date:  2007-11-02       Impact factor: 22.113

10.  Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.

Authors:  Giovanni Palladini; Efstathios Kastritis; Mathew S Maurer; Jeffrey Zonder; Monique C Minnema; Ashutosh D Wechalekar; Arnaud Jaccard; Hans C Lee; Naresh Bumma; Jonathan L Kaufman; Eva Medvedova; Tibor Kovacsovics; Michael Rosenzweig; Vaishali Sanchorawala; Xiang Qin; Sandra Y Vasey; Brendan M Weiss; Jessica Vermeulen; Giampaolo Merlini; Raymond L Comenzo
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.